PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31876149-0	2020	KPT-9274, an inhibitor of PAK4 and NAMPT, leads to downregulation of mTORC2 in triple negative breast cancer cells.	selinexor	0-8	nicotinamide phosphoribosyltransferase	Homo sapiens	35-40	
31876149-3	2020	KPT-9274 is a dual specific inhibitor of PAK4 and Nicotinamide Phosphoribosyltransferase (NAMPT).	selinexor	0-8	nicotinamide phosphoribosyltransferase	Homo sapiens	50-88	
31876149-3	2020	KPT-9274 is a dual specific inhibitor of PAK4 and Nicotinamide Phosphoribosyltransferase (NAMPT).	selinexor	0-8	nicotinamide phosphoribosyltransferase	Homo sapiens	90-95	
31795447-5	2019	Treatment with KPT-9274 (currently in a Phase I trial or analogs, PF3758309 (the PAK4 selective inhibitor) or FK866 (the NAMPT inhibitor)) suppressed the growth of PNET cell lines and synergized with the mammalian target of rapamycin (mTOR) inhibitors everolimus and INK-128.	selinexor	15-23	nicotinamide phosphoribosyltransferase	Homo sapiens	121-126